News

The company has earned net profit of INR4.43bn, resulting into a net margin of 30%. The company has posted net sales of INR57.21bn for the financial year ended

The study evaluated NCX 226, in comparison with bosentan, in a preclinical model of pulmonary fibrosis induced by bleomycin. The results of the trial suggested that NCX 226

The Solesta gel is injected into a layer of tissue beneath the anus lining and may help build tissue in that area. The FDA approval was given on

The agreement covers kinetoplastid diseases (leishmaniases, Chagas disease, and human African trypanosomiasis), helminth infections (lymphatic filariasis, onchocerciasis, and soil-transmitted helminthiasis), and dracunculiasis, fascioliasis, and schistosomiasis diseases. Under the

Earlier, Johns Hopkins University has licensed FP01 intellectual property to Fells Labs. As per the terms of the current agreement, Fells Labs is entitled to get an upfront

The CBORD Group, which operates as a unit of Roper Industries, serves healthcare facilities, colleges and universities, chain restaurants, supermarkets, senior living facilities, corporations, and a host of

As per the terms of the agreement, ProMetic will be responsible to accelerate an affinity resin product and associated manufacturing process conditions for its client. The agreement will

Dificid tablets are indicated for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age or older. The FDA approval was given on the basis

The high dose cohort (3 mg/kg/dose) Phase II trial expects to recruit around 21 patients in the trial. The company anticipates to release the top line results of